Print this page    •   Back to Web version of article

Vicriviroc Fails for the Treatment Experienced

February 2010

Unfortunate news was recently released by Merck on their experimental co-receptor antagonist, vicriviroc, which might have provided another option as the second R5 drug, just behind Selzentry (maraviroc). The company will not move forward for FDA approval given the disappointing results from 2 large studies (VICTOR-E3 and -E4) in treatment-experienced people. Complete data will be released at CROI (Conference on Retroviruses and Opportunistic Infections) in February 2010.

Both studies followed people who had been on therapy before. Everyone was on effective HIV therapy (3 or more active drugs) and was then randomly assigned to take vicriviroc or placebo. A press release by the company stated that the studies did not meet their main goal, most likely not keeping HIV under control and below 50 copies over time. Vicriviroc is still being studied in those starting their first HIV regimen.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art55663.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.